Jed A. Latkin
2021
In 2021, Jed A. Latkin earned a total compensation of $1.3M as Former Chief Executive Officer, Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals, a 10% increase compared to previous year.
Compensation breakdown
| Option Awards | $187,849 |
|---|---|
| Salary | $408,333 |
| Other | $750,908 |
| Total | $1,347,090 |
Latkin received $750.9K in other compensation, accounting for 56% of the total pay in 2021.
Latkin also received $187.8K in option awards and $408.3K in salary.
Rankings
In 2021, Jed A. Latkin's compensation ranked 7,679th out of 12,397 executives tracked by ExecPay. In other words, Latkin earned more than 38.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,679 out of 12,397 | 38th |
Division Manufacturing | 3,380 out of 5,492 | 39th |
Major group Chemicals And Allied Products | 1,495 out of 2,367 | 37th |
Industry group Drugs | 1,330 out of 2,090 | 36th |
Industry In Vitro and In Vivo Diagnostic Substances | 28 out of 61 | 54th |
Source: SEC filing on October 24, 2022.
Latkin's colleagues
We found four more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2021.
2021
Michael Rosol
Navidea Biopharmaceuticals
Chief Medical Officer
2021
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
2021
Michel Mikhail
Navidea Biopharmaceuticals
Chief Regulatory Officer
2021
Joel Kaufman
Navidea Biopharmaceuticals
Former Chief Business Officer
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019